The Effective of Potassium Sodium Hydrogen Citrate in Treating Uric Acid Stones Using Gut Microbiota and Metabolomics.

Launched by CHENG CAO · Oct 31, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called potassium sodium hydrogen citrate can help patients with uric acid stones, which are a type of kidney stone. The researchers want to understand how this treatment affects the gut bacteria and the substances produced in the body (metabolites) after taking the medication. Participants will take the medication for three months and will need to provide samples of their blood, urine, and stool before and after the treatment to help the researchers learn more about how the medication works.

To be eligible for this trial, patients must have been diagnosed with uric acid stones through specific imaging tests like ultrasounds or CT scans. They should not have certain health issues, such as cancer or liver problems, and should not have taken specific medications like statins recently. Participants can expect to take the medication for three months and contribute samples for analysis, helping to uncover important information that might improve treatment for uric acid stones in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All stone patients were diagnosed using urologic ultrasonography, kidney-ureter-bladder (KUB) X-ray, or abdominal computed tomography (CT). Stone samples were obtained through ureteroscopic lithotripsy (URSL), percutaneous nephrolithotomy (PCNL), or extracorporeal shock wave lithotripsy (ESWL). Stones were analyzed using an automated infrared spectroscopy system, LIIR-20 (Lanmode Scientific Instrument Co., Ltd., Tianjin, China), and the main components were determined based on the most abundant substances listed in the report, which were classified as pure or mixed uric acid stones (anhydrous uric acid content \>50%).
• Exclusion Criteria:
• • Patients with malignancy, chronic liver insufficiency, a history of statin use, and thyroid or parathyroid disease were excluded from the study. Similarly, individuals with a history of urolithiasis or dyslipidemia as well as those who had used statins were excluded from the control group. Participants were also excluded if they had taken antibiotics or immune suppressants within one month prior to fecal sampling, or had a history of chronic diarrhea or constipation, chronic enteritis, irritable bowel syndrome, gastrointestinal tumors or intestinal surgery.